Ceftriaxone 500mg IM for Gonorrhea in an 18-Year-Old Woman
Yes, an 18-year-old woman can receive ceftriaxone 500mg IM for uncomplicated gonorrhea, and this dose is now the CDC-recommended standard for all adults regardless of weight. 1
Current CDC Recommendation
- The CDC now recommends ceftriaxone 500mg IM as a single dose for uncomplicated gonococcal infections of the cervix, urethra, rectum, and pharynx in all adults. 1, 2
- This represents an increase from the previous 250mg dose, driven by antimicrobial stewardship principles and evolving resistance patterns. 1, 2
- The 500mg dose achieves a 99.1% cure rate for urogenital and anorectal infections. 1, 3
Mandatory Co-Treatment for Chlamydia
- If chlamydial co-infection has not been excluded, add doxycycline 100mg orally twice daily for 7 days. 1, 2
- Azithromycin 1g orally as a single dose is an alternative, though doxycycline is now preferred due to rising azithromycin resistance (nearly 5% of isolates in 2018 had elevated MICs ≥2.0 mcg/mL). 1, 2
- Co-infection with Chlamydia trachomatis occurs in 10-50% of gonorrhea cases, making presumptive dual therapy essential. 1
Weight Considerations
- Ceftriaxone dosing for uncomplicated gonorrhea is NOT weight-based; the same 500mg dose is used across all adult body weights. 3
- Clinical trials using 125-250mg ceftriaxone across patients of varying weights reported cure rates of 98.9-99.1%, confirming adequacy regardless of weight. 3
- Even in patients weighing 156kg, no dose adjustment is required for uncomplicated infection. 3
Administration Details
- Administer as a single intramuscular injection into a large muscle mass (e.g., gluteus maximus or lateral thigh). 4
- The injection is painful; consider using 1% lidocaine as a diluent to reduce discomfort. 1
- Intravenous administration is equally effective and may be used if the patient refuses IM injection, though IM is standard for uncomplicated cases. 1, 4
Site-Specific Efficacy
- Ceftriaxone 500mg is the only reliably effective treatment for pharyngeal gonorrhea, which is more difficult to eradicate than urogenital infections. 1
- Oral cephalosporins (e.g., cefixime) achieve only 78.9% cure for pharyngeal infections versus 99.1% for ceftriaxone. 1, 3
- If pharyngeal exposure is possible, ceftriaxone is mandatory—alternative regimens are inadequate. 1
Partner Management
- All sexual partners from the preceding 60 days must be evaluated and treated with the same regimen (ceftriaxone 500mg IM + doxycycline or azithromycin), regardless of symptoms or test results. 1
- Patients must abstain from sexual intercourse until therapy is completed and both they and all partners are asymptomatic. 1
Follow-Up Testing
- Routine test-of-cure is NOT required for patients receiving the recommended ceftriaxone-based regimen unless symptoms persist. 1
- Retest all patients at 3 months due to high reinfection rates (20-30%). 1
- If symptoms persist after treatment, obtain culture with antimicrobial susceptibility testing from all potentially infected sites. 1
Contraindicated Alternatives
- Never use fluoroquinolones (ciprofloxacin, ofloxacin) for gonorrhea due to widespread resistance, despite historical cure rates >99%. 5, 1
- Never use azithromycin 1g alone—it has only 93% efficacy and promotes rapid resistance development. 1
- Spectinomycin has only 52% efficacy for pharyngeal infections and should be avoided when pharyngeal exposure is possible. 1
Severe Cephalosporin Allergy
- For patients with severe β-lactam allergy, azithromycin 2g orally as a single dose is the only alternative, but it has lower efficacy (≈93%) and requires mandatory test-of-cure at 1 week. 1
- Gentamicin 240mg IM + azithromycin 2g orally is another alternative with 100% cure rate in trials, but should be reserved for documented treatment failure. 1
Additional Screening
- Screen for syphilis by serology and HIV at the time of gonorrhea diagnosis, as gonorrhea facilitates HIV transmission. 1
Practical Algorithm
- Administer ceftriaxone 500mg IM immediately (single dose). 1, 2
- Add doxycycline 100mg orally twice daily for 7 days if chlamydia not excluded. 1, 2
- Counsel patient to notify all sexual partners from preceding 60 days for evaluation and treatment. 1
- Advise abstinence until therapy completed and both patient and partners asymptomatic. 1
- Retest at 3 months due to high reinfection risk. 1
- Screen for syphilis and HIV at initial visit. 1